Comparing Protease Combinations

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Treatment Action Group

Comparing Protease Combinations

May 1996

Reported maximum average reductions in plasma RNA with selected protease inhibitor combinations (in treament naive/experienced* individuals)
SQV	.6 log	S. Vella
SQV(new formulation)	1.5 log	Roche
RTV	1.2-1.9 log	Abbott
IDV	1.2-2.0 log	Merck
NFV	1.5 log	Markowitz
SQV+AZT	1.0 log	S. Vella
SQV+ddC	.6 log	Roche NV*
SQV+AZT+ddC	.8 log	ACTG 229*
RTV+AZT	1.2 log	Abbott
RTV+AZT+ddC	2.0-2.5 log	Leibowich
IDV+AZT	1.4-1.5 log	Merck
IDV+AZT+ddl	2.9 log	Merck
IDV+AZT3TC	>2.0 log	Merck 035*
NFV+d4T	2.4-2.6 log	Chapman

This article was provided by Treatment Action Group. It is a part of the publication TAGline.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.